chimeric antigen receptor gene modified T cells

Developed for: B-cell non-Hodgkin lymphoma · acute lymphoblastic leukemia · peripheral T-cell lymphoma, not otherwise specified · refractory plasma cell neoplasm
Investigated by: Shanxi Bethune Hospital · First Affiliated Hospital of Guangxi Medical University · Shandong Qilu Cell Therapy Engineering Technology Co., Ltd · Tongji Hospital Affiliated to Tongji Medical College of HUST · Wuhan Central Hospital · Yichang Central People's Hospital

202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT07048353	Jul 2025 → Jul 2029 expected	B-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified	Shandong Qilu Cell Therapy Engineering Technology Co., Ltd	Not yet recruiting	No outcome recorded
Phase not applicable2 trials
—	NCT06850285	Sep 2025 → Jun 2028 expected	B-cell non-Hodgkin lymphoma	Shanxi Bethune Hospital	Recruiting	No outcome recorded
—	NCT06783816	Dec 2023 → Jun 2028 expected	acute lymphoblastic leukemia, refractory plasma cell neoplasm	Shanxi Bethune Hospital	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	chimeric antigen receptor gene modified T cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06850285 ↗ 2 NCT06783816 ↗ NCT07048353 ↗
Modality	Cell therapy	“novel CAR-T therapy” NCT06783816 ↗
Route	Intravenous	“The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min” NCT06783816 ↗